ARIZ and NATA Announce Collaboration to develop multiple targeted nucleic acid therapies for cancer treatment
November 23, 2024
DAVIS, CA, UNITED STATES, November 21, 2024 /EINPresswire.com/ — The pioneering precision medicine company, ARIZ Precision Medicine (ARIZ), and the Medical Research Council’s Nucleic Acid Therapy Accelerator (NATA), today announced a collaboration to harness their platforms to develop nucleic acid therapy (NAT) drug candidates for novel gene targets with strong genetic associations to leading cancers. The collaboration combines NATA’s expertise in NAT design and ARIZ’s RNAi compounds, which are being developed to treat a range of cancers.